Roflumilast: Clinical benefit in patients suffering from COPD

Clinical Respiratory Journal

Volumn 4, Issue 4, 2010, Pages 197-201

  Ulrik, Charlotte Suppli ^a   Calverley, Peter Michael Anthony ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

Author keywords

COPD; exacerbations; lung function; roflumilast

Indexed keywords

CORTICOSTEROID; ROFLUMILAST; SALMETEROL;

APPETITE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EFFECTIVENESS; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SUBSTITUTION; DRUG TOLERABILITY; FORCED EXPIRATORY VOLUME; HUMAN; INFLAMMATION; LUNG FUNCTION; MORBIDITY; MORTALITY; NAUSEA; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SIDE EFFECT; WEIGHT REDUCTION;

AMINOPYRIDINES; BENZAMIDES; CLINICAL TRIALS AS TOPIC; CYCLOPROPANES; HUMANS; PHOSPHODIESTERASE 4 INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 77957578677     PISSN: 17526981     EISSN: 1752699X     Source Type: Journal    
DOI: 10.1111/j.1752-699X.2010.00224.x     Document Type: Review

References (16)

1. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004 23 : 932 46.
2. O'Donnell DE, Hernandez P, Kaplan A, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease-2008 update-highlights for primary care. Can Respir J. 2008 15 (Suppl. A 1A 8A.
3. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007 176 : 532 55.
4. Barónes PJ, Stockley RA. COPD: current therapeutic interventions and future approaches. Eur Respir J. 2005 6 : 1084 106.
5. Rennard SI. Treatment of stable chronic obstructive pulmonary disease. Lancet. 2004 364 : 791 802.
6. Grootendorst DC, Gauw SA, Verhoosel RM, et al. Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax. 2007 62 : 1081 7.
7. Rabe KF, Batemann ED, O'Donnell D, et al. Roflumilast - an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2005 366 : 563 71.
8. Calverley PMA, Sanchez-Toril F, Mcivor A, et al. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007 176 : 154 61.
9. Calverley PAM, Rabe KF, Goehring UM, et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet. 2009 374 : 685 94.
10. Fabbri LM, Calverley PAM, Izquierdo-Alonsa JL, et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with long acting bronchodilators: two randomised clinical trials. Lancet. 2009 374 : 695 703.
11. th International Multidisciplinary Conference of COPD, Birmingham, UK, 2010.
12. th International Multidisciplinary Conference of COPD, Birmingham, UK, 2010.
13. Donohue JF. Minimal clinically important differences in COPD: lung function. COPD. 2005 2 : 111 24.
14. Jenkins CR, Jones PW, Calverley PAM, et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res. 2009 10 : 59.
15. Crim C, Calverley PAM, Anderson JA, et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J. 2009 34 : 641 7.
16. Calverley PAM, Sockley RA, Seemungal TA, et al. Reported pneumonia in COPD: findings from the INSPIRE study. Chest. 2010 doi:10.1378/chest.09-2992.